Host |
Rat |
Klon |
RM80 |
Format |
Purified |
Methode |
F, FL |
Isotyp |
Rat IgG2a |
Verdünnung |
BCL1 cells expressing CD80 |
CD80
|
Zytomed Systems GmbH |
RM80 |
250 µg |
Purified |
RUO |
603-2340 |
-
|
Host |
Mouse |
Klon |
B-L2 |
Format |
Purified |
Methode |
F, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
CD82 transfected murine mastocytoma cell line P815 |
CD82
|
Zytomed Systems GmbH |
B-L2 |
200 Tests |
Purified |
RUO |
603-1390 |
-
|
Host |
Mouse |
Klon |
BU63 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human peripheral blood lymphocytes |
CD86 (B7-2)
|
Zytomed Systems GmbH |
BU63 |
200 µg |
Purified |
RUO |
603-1396 |
-
|
Host |
Mouse |
Klon |
F15-42-1 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Purified human brain Thy-1 |
CD90 (Thy-1)
|
Zytomed Systems GmbH |
F15-42-1 |
200 µg |
Purified |
RUO |
603-1435 |
-
|
Host |
Mouse |
Klon |
OX-7 |
Format |
Purified |
Methode |
F, WB, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Rat Thy-1 antigen |
CD90 (Thy-1)
|
Zytomed Systems GmbH |
OX-7 |
1 mg |
Purified |
RUO |
603-1439 |
-
|
Host |
Mouse |
Klon |
OX-7 |
Format |
Purified |
Methode |
FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Rat Thy-1 antigen |
CD90 (Thy-1) - FITC
|
Zytomed Systems GmbH |
OX-7 |
50 µg |
Purified |
RUO |
603-1446C |
-
|
Host |
Mouse |
Klon |
VIM-15b |
Format |
Purified |
Methode |
FL |
Verdünnung |
1:5 |
Isotyp |
Mouse IgG2b |
Verdünnung |
MV4-11 acute monocyte leukaemai cells |
CD92 - FITC
|
Zytomed Systems GmbH |
VIM-15b |
100 µg |
Purified |
RUO |
603-2356 |
-
|
Host |
Rabbit |
Klon |
EP8 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide to residues on the C-terminus |
Lokalisation |
Cell membrane, cytoplasm |
CD99
|
Biocare Medical |
EP8 |
0.1 ml |
Concentrate |
CE/IVD |
CME392A |
-
|
Host |
Mouse |
Klon |
HO36-1.1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Sarcom |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
CD99
|
Diagnostic Biosystems |
HO36-1.1 |
1 ml |
Concentrate |
CE/IVD |
MOB262 |
-
|
Host |
Mouse |
Klon |
HO36-1.1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Sarcom |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
CD99
|
Diagnostic Biosystems |
HO36-1.1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB262-01 |
-
|
Host |
Mouse |
Klon |
HO36-1.1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Sarcom |
Verdünnung |
1:25 - 1:75 |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
CD99
|
Diagnostic Biosystems |
HO36-1.1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB262-05 |
-
|
Host |
Mouse |
Klon |
HO36-1.1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Sarcom |
Verdünnung |
- |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
CD99
|
Diagnostic Biosystems |
HO36-1.1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM106 |
-
|
Host |
Rabbit |
Klon |
EP8 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide to residues on the C-terminus |
Lokalisation |
Cell membrane, cytoplasm |
CD99
|
Biocare Medical |
EP8 |
6 ml |
Ready-to-use |
CE/IVD |
PME392AA |
-
|
Host |
Mouse |
Klon |
ZM139 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ewing’s sarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa1-185) of human MIC2 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface |
CD99
|
Zeta Corporation |
ZM139 |
1 ml |
Concentrate |
CE/IVD |
Z2686ML |
-
|
Host |
Mouse |
Klon |
ZM139 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ewing’s sarcoma |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa1-185) of human MIC2 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface |
CD99
|
Zeta Corporation |
ZM139 |
7 ml |
Concentrate |
CE/IVD |
Z2686MP |
-
|
Host |
Mouse |
Klon |
ZM139 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ewing’s sarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa1-185) of human MIC2 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface |
CD99
|
Zeta Corporation |
ZM139 |
0.5 ml |
Concentrate |
CE/IVD |
Z2686MS |
-
|
Host |
Mouse |
Klon |
ZM139 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ewing’s sarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa1-185) of human MIC2 protein (exact sequence is proprietary) |
Lokalisation |
Cell surface |
CD99
|
Zeta Corporation |
ZM139 |
0.1 ml |
Concentrate |
CE/IVD |
Z2686MT |
-
|
Host |
Rabbit |
Klon |
EP206 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hairy cell leukemia |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the residues of human CD103 protein |
Lokalisation |
Cell membrane |
CD103
|
Biocare Medical |
EP206 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3117A |
-
|
Host |
Rabbit |
Klon |
EP206 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hairy cell leukemia |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the residues of human CD103 protein |
Lokalisation |
Cell membrane |
CD103
|
Biocare Medical |
EP206 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3117B |
-
|
Host |
Rabbit |
Klon |
EP206 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hairy cell leukemia |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the residues of human CD103 protein |
Lokalisation |
Cell membrane |
CD103
|
Biocare Medical |
EP206 |
6 ml |
Ready-to-use |
CE/IVD |
API3117AA |
-
|
Host |
Rabbit |
Klon |
ZR404 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Isotyp |
IgG |
Verdünnung |
Recombinant human ITGAE/CD103 protein fragment (aa 775-855) |
Lokalisation |
Cell Surface and cytoplasmic |
CD103
|
Zeta Corporation |
ZR404 |
7 ml |
ready-to-use |
RUO |
Z2760RP-R |
-
|
Host |
Mouse |
Klon |
LF61 |
Format |
Lyophilised |
Methode |
FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Hairy cell leukaemia cells |
CD103 (Integrin alpha E) - PE
|
Zytomed Systems GmbH |
LF61 |
100 Tests |
Lyophilised |
RUO |
603-1521E |
-
|
Host |
Mouse |
Klon |
SN6 |
Format |
Purified |
Methode |
F, WB, IP, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Partially purified cell membrane antigens from fresh leukaemia cells |
CD105 (Endoglin, TGF-beta1/3-Receptor)
|
Zytomed Systems GmbH |
SN6 |
200 µg |
Purified |
RUO |
603-1530 |
-
|
Host |
Mouse |
Klon |
ZM321 |
Format |
Concentrate |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
: Gastrointestinal stromal tumor (GIST), skin or tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa 50-250) of human KIT protein |
Lokalisation |
Cell membrane |
CD117
|
Zeta Corporation |
ZM321 |
1.0 ml |
Concentrate |
CE/IVD |
Z2628ML |
-
|
Host |
Mouse |
Klon |
ZM321 |
Format |
ready-to-use |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
Gastrointestinal stromal tumor (GIST), skin or tonsil |
Verdünnung |
--- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa 50-250) of human KIT protein |
Lokalisation |
cell membrane |
CD117
|
Zeta Corporation |
ZM321 |
7 ml |
ready-to-use |
CE/IVD |
Z2628MP |
-
|
Host |
Mouse |
Klon |
ZM321 |
Format |
Concentrate |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
Gastrointestinal stromal tumor (GIST), skin or tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa 50-250) of human KIT protein |
Lokalisation |
Cell membrane |
CD117
|
Zeta Corporation |
ZM321 |
0.5 ml |
Concentrate |
CE/IVD |
Z2628MS |
-
|
Host |
Mouse |
Klon |
ZM321 |
Format |
Concentrate |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
Gastrointestinal stromal tumor (GIST), skin or tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa 50-250) of human KIT protein |
Lokalisation |
cell membrane |
CD117
|
Zeta Corporation |
ZM321 |
0.1 ml |
Concentrate |
CE/IVD |
Z2628MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Stromal Tumor, Skin |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from the cytoplasmic domain of human CD117 / c-kit protein. |
Lokalisation |
Cell Membrane |
CD117/c-kit
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
503-1440 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Stromal Tumor, Skin |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from the cytoplasmic domain of human CD117 / c-kit protein. |
Lokalisation |
Cell Membrane |
CD117/c-kit
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
503-1442 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Stromal Tumor, Skin |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from the cytoplasmic domain of human CD117 / c-kit protein. |
Lokalisation |
Cell Membrane |
CD117/c-kit
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
503-1444 |
-
|
Host |
Rabbit |
Klon |
EP10 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
ER2 |
Positivkontrolle |
Skin, gastrointestinal tumour |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
6 ml |
Ready-to-use |
CE/IVD |
ALI296G7 |
-
|
Host |
Rabbit |
Klon |
EP10 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, gastrointestinal tumour |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
0.1 ml |
Concentrate |
CE/IVD |
CME296AK |
-
|
Host |
Rabbit |
Klon |
EP10 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, gastrointestinal tumour |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
0.5 ml |
Concentrate |
CE/IVD |
CME296BK |
-
|
Host |
Rabbit |
Klon |
EP10 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, gastrointestinal tumour |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
1 ml |
Concentrate |
CE/IVD |
CME296CK |
-
|
Host |
Rabbit |
Klon |
EP10 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, gastrointestinal tumour |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane, cytoplasmic |
CD117/c-kit
|
Biocare Medical |
EP10 |
6 ml |
Ready-to-use |
CE/IVD |
PME296AA |
-
|
Host |
Rabbit |
Klon |
DBRRM1.17 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
optional |
Positivkontrolle |
1:100-1:200 |
Verdünnung |
EDTA |
Isotyp |
IgG, Kappa |
Verdünnung |
Recombinant human full KIT protein fragments (around aa 50- 200) |
Lokalisation |
Cytoplasmic, cell surface |
CD117/c-kit
|
Diagnostic Biosystems |
DBRRM1.17 |
1 ml |
Concentrate |
CE/IVD |
RMAB119 |
-
|
Host |
Rabbit |
Klon |
DBRRM1.17 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
optional |
Positivkontrolle |
1:100-1:200 |
Verdünnung |
EDTA |
Isotyp |
IgG, Kappa |
Verdünnung |
Recombinant human full KIT protein fragments (around aa 50- 200) |
Lokalisation |
Cytoplasmic, cell surface |
CD117/c-kit
|
Diagnostic Biosystems |
DBRRM1.17 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB119-01 |
-
|
Host |
Rabbit |
Klon |
DBRRM1.17 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
optional |
Positivkontrolle |
1:100-1:200 |
Verdünnung |
EDTA |
Isotyp |
IgG, Kappa |
Verdünnung |
Recombinant human full KIT protein fragments (around aa 50- 200) |
Lokalisation |
Cytoplasmic, cell surface |
CD117/c-kit
|
Diagnostic Biosystems |
DBRRM1.17 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB119-05 |
-
|
Host |
Rabbit |
Klon |
DBRRM1.17 |
Format |
ready-to-use |
Methode |
P |
Vorbehandlung |
optional |
Positivkontrolle |
--- |
Verdünnung |
EDTA |
Isotyp |
IgG, Kappa |
Verdünnung |
Recombinant human full KIT protein fragments (around aa 50- 200) |
Lokalisation |
Cytoplasmic, cell surface |
CD117/c-kit
|
Diagnostic Biosystems |
DBRRM1.17 |
6 ml |
ready-to-use |
CE/IVD |
RMPD119 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM80 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or thymus. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment of human IL3RA protein (around aa 26-171) |
Lokalisation |
Cytoplasm |
CD123
|
Zeta Corporation |
ZM80 |
1 ml |
Concentrate |
CE/IVD |
Z2390ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM80 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or thymus. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment of human IL3RA protein (around aa 26-171) |
Lokalisation |
Cytoplasm |
CD123
|
Zeta Corporation |
ZM80 |
7 ml |
Ready-to-use |
CE/IVD |
Z2390MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM80 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or thymus. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment of human IL3RA protein (around aa 26-171) |
Lokalisation |
Cytoplasm |
CD123
|
Zeta Corporation |
ZM80 |
0.5 ml |
Concentrate |
CE/IVD |
Z2390MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM80 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lymph node or thymus. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant fragment of human IL3RA protein (around aa 26-171) |
Lokalisation |
Cytoplasm |
CD123
|
Zeta Corporation |
ZM80 |
0.1 ml |
Concentrate |
CE/IVD |
Z2390MT |
-
|
Host |
Mouse |
Klon |
BBK-2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, small intestine with Peyer's patches |
Verdünnung |
1:100 |
Isotyp |
IgG1 kappa |
Verdünnung |
Ectodomain of human 4-1BB recombinant protein |
Lokalisation |
Cell membrane |
CD137
|
Biocare Medical |
BBK-2 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3201A |
-
|
Host |
Mouse |
Klon |
BBK-2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, small intestine with Peyer's patches |
Verdünnung |
1:100 |
Isotyp |
IgG1 kappa |
Verdünnung |
Ectodomain of human 4-1BB recombinant protein |
Lokalisation |
Cell membrane |
CD137
|
Biocare Medical |
BBK-2 |
0.5 ml |
Concentrate |
CE/IVD |
ACI3201B |
-
|
Host |
Mouse |
Klon |
BBK-2 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, small intestine with Peyer's patches |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Verdünnung |
Ectodomain of human 4-1BB recombinant protein |
Lokalisation |
Cell membrane |
CD137
|
Biocare Medical |
BBK-2 |
6 ml |
Ready-to-use |
CE/IVD |
API3201AA |
-
|
Host |
Rabbit |
Klon |
ZR251 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa1-250) of human CD138 protein |
Lokalisation |
Cell Membrane |
CD138
|
Zeta Corporation |
ZR251 |
1 ml |
Concentrate |
CE/IVD |
Z2490RL |
-
|
Host |
Rabbit |
Klon |
ZR251 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa1-250) of human CD138 protein |
Lokalisation |
Cell Membrane |
CD138
|
Zeta Corporation |
ZR251 |
7 ml |
Concentrate |
CE/IVD |
Z2490RP |
-
|
Host |
Rabbit |
Klon |
ZR251 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa1-250) of human CD138 protein |
Lokalisation |
Cell Membrane |
CD138
|
Zeta Corporation |
ZR251 |
0.5 ml |
Concentrate |
CE/IVD |
Z2490RS |
-
|
Host |
Rabbit |
Klon |
ZR251 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa1-250) of human CD138 protein |
Lokalisation |
Cell Membrane |
CD138
|
Zeta Corporation |
ZR251 |
0.1 ml |
Concentrate |
CE/IVD |
Z2490RT |
-
|